Last updated July 2026 — reflects the new Medicare GLP-1 Bridge.
When the Medicare Part D drug benefit was created, Congress excluded several categories of drugs by statute — and "agents when used for weight loss" is one of them. That exclusion still stands in 2026. So even though Wegovy is FDA-approved and widely prescribed, a Part D plan generally cannot pay for it when the reason is weight management. This is a legal rule, not a medical-necessity judgment — which is why it applies across nearly every plan regardless of your doctor's documentation.
There's now a narrow, temporary path to a GLP-1 for weight management on Medicare. On July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a time-limited demonstration that lets eligible Part D members get certain GLP-1s — including Wegovy — for a flat $50 a month, running through December 31, 2027. Who qualifies: a BMI of 35 or higher automatically, or 27 or higher with a related condition such as heart disease or prediabetes. Two catches worth knowing: the $50 copay doesn't count toward your deductible or out-of-pocket maximum, and Extra Help can't be applied to it. CMS publishes the exact list of covered drugs and doses on its "Medicare GLP-1 Bridge" page.
The Bridge is what remained after CMS's broader BALANCE Model stalled — the Part D portion of BALANCE was delayed indefinitely when major insurers declined to participate, so the Bridge was extended through the end of 2027 as the interim path. It's a real opening, but a time-limited one — not permanent Part D coverage.
This is the exception that matters. In 2024 the FDA approved Wegovy to reduce the risk of cardiovascular events — heart attack and stroke — in adults with established cardiovascular disease who are also overweight or obese. Because that's a cardiovascular indication and not "weight loss," Medicare Part D can cover Wegovy for it, and that's largely what the small share of Part D plans listing Wegovy are actually covering. Expect it on a high specialty tier with prior authorization, and expect the plan to require documentation of your established heart disease. So the honest answer: Medicare won't cover Wegovy to lose weight, but it may cover the very same drug to lower your cardiovascular risk if you have known heart disease. If that's you, ask your plan and prescriber whether you qualify under the cardiovascular indication — it's a different door with a different answer.
It comes down to the approved use, not the molecule. Ozempic (semaglutide — the same active ingredient as Wegovy) is approved for type 2 diabetes and is covered on roughly 99% of Part D plans. Mounjaro (tirzepatide, for diabetes) is similar. Their weight-loss-branded twins — Wegovy and Zepbound — are the ones that hit the statutory exclusion. See the Ozempic breakdown →
See how any medication lands across all Medicare Part D plans — coverage, tier, and prior authorization.
Look up a drug — freeStandard Part D still can't, by statute. But as of July 1, 2026, a time-limited Medicare demonstration — the GLP-1 Bridge — offers eligible members certain GLP-1s (including Wegovy) for $50 a month for weight management, running through December 31, 2027. It's an exception with its own eligibility rules, not a permanent change to Part D.
It can. Following the 2024 FDA approval for cardiovascular risk reduction, some Part D plans cover Wegovy for that indication — typically on a high specialty tier with prior authorization. Ask your plan whether you qualify based on your cardiovascular history.
The list price runs well over $1,000 per month. If your plan won't cover it, the new $50 GLP-1 Bridge may be an option if you qualify, or ask your prescriber about manufacturer savings programs (often limited for people on Medicare). Separately, semaglutide (Ozempic, Rybelsus, Wegovy) is in Medicare's drug price negotiation, with lower negotiated prices taking effect January 2027 — Ozempic drops to about $274 a month from a roughly $959 list price.
Yes — for type 2 diabetes, Ozempic is on roughly 99% of Part D plans, usually Tier 3 with prior authorization. More on Ozempic coverage →